Physician profile
Jose Medrano
NPI 1801880786
$10,989.36
in general payments reported to CMS, 2019-2025
34 companies · $4,168 in 2025
The $4,168 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $421 · 2021: $972 · 2022: $633 · 2023: $342 · 2024: $3,817 · 2025: $4,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,000 · Food and Beverage: $1,140 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,000.00 |
| Food and Beverage | $1,139.57 |
| Education | $186.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $7,000.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $988.33 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $321.37 | 2021-2025 | |
| Therapeuticsmd, INC. | $278.58 | 2019-2022 | |
| Astellas Pharma US INC | $254.91 | 2025 | Veozah |
| Evofem Biosciences, INC. | $250.51 | 2021-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $193.45 | 2020-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Pfizer INC. | $182.32 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.94 | 2019-2022 | |
| Exeltis, USA INC. | $148.32 | 2019-2025 | Slynd |
| Organon LLC | $132.29 | 2024-2025 | Nexplanon |
| Coopersurgical, INC. | $109.63 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Myovant Sciences INC. | $106.76 | 2021-2022 | |
| Sage Therapeutics, LLC | $82.58 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $79.48 | 2021-2024 | Twirla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $78.26 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $72.23 | 2023-2025 | Myfembree |
| Coloplast Corp | $71.27 | 2022 | |
| Lupin INC. | $70.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $65.26 | 2023 | Xarelto |
| Baxter Healthcare | $60.54 | 2023-2024 | Perclot, Tisseel |
| Merck Sharp & Dohme LLC | $57.85 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $52.23 | 2024-2025 | |
| Antares Pharma, INC. | $24.37 | 2021 | |
| Smith+Nephew, INC. | $23.82 | 2025 | Pico |
| Ethicon US, LLC | $21.81 | 2023 | Ethicon |
| Supernus Pharmaceuticals, INC. | $19.57 | 2025 | Qelbree |
| Mission Pharmacal Company | $19.54 | 2019 | |
| Shield Therapeutics INC | $19.41 | 2023 | Accrufer |
| Millicent US INC | $18.13 | 2025 | Femlyv, Intrarosa |
| Scynexis, INC. | $16.72 | 2022 | |
| Meditrina | $15.13 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Medrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.